CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to COVID-19 will focus on the prevention and treatment of Post COVID-19 Conditions (PCC), colloquially known as long-COVID, as opposed to hospitalized COVID-19 patients, reflecting the compelling opportunity for apabetalone to benefit PCC patients and guidance from the US Food and Drug Administration (FDA).
VANCOUVER, BC / ACCESSWIRE / February 22, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Else Nutrition, Ayurcann Holdings, and Resverlogix on their latest news. The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives. Else Nutrition (TSX:BABY)
Small-cap earnings are coming in better than expected. The economy continues to churn out strong numbers. But small-caps, which by nature have larger domestic exposure, continue to trade within a five-month range.
